Annual report
9158.TEDINET S100W87M
Period2024-04-01 → 2025-03-31
Filed2025-06-27
StandardIFRS
ConsolidatedYes
Data checks21 of 21 passed
Key figures · 147
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥47.0bn | 2024-04-01 → 2025-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥33.0bn | 2023-04-01 → 2024-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥35.2bn | 2022-04-01 → 2023-03-31v | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥35.3bn | 2021-04-01 → 2022-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥16.6bn | 2020-04-01 → 2021-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Operating income | ¥5.3bn | 2024-04-01 → 2025-03-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥3.7bn | 2023-04-01 → 2024-03-31 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥5.2bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥4.1bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥3.6bn | 2022-04-01 → 2023-03-31v | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥3.6bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥1.6bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Net income (owners) | ¥3.1bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥2.6bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥2.4bn | 2022-04-01 → 2023-03-31v | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥2.7bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥1.1bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income | ¥3.1bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss IFRS |
| Net income | ¥2.6bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss IFRS |
| Total assets | ¥85.2bn | at 2025-03-31 | Cons. | Assets IFRS |
| Total assets | ¥62.8bn | at 2024-03-31 | Cons. | Assets IFRS |
| Total assets | ¥39.8bn | at 2023-03-31v | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥34.5bn | at 2022-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥28.4bn | at 2021-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥54.9bn | at 2025-03-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥34.8bn | at 2024-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥30.3bn | at 2025-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥28.0bn | at 2024-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥11.9bn | at 2023-03-31v | Cons. | Equity IFRS |
| Equity (owners) | ¥29.7bn | at 2025-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥27.3bn | at 2024-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥11.7bn | at 2023-03-31v | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥9.5bn | at 2022-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥4.7bn | at 2021-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥7.5bn | at 2025-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥8.3bn | at 2024-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥4.1bn | at 2023-03-31v | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥4.4bn | at 2022-03-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Cash & equivalents | ¥3.6bn | at 2021-03-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Operating cash flow | ¥2.5bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥4.2bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥2.4bn | 2022-04-01 → 2023-03-31v | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥6.6bn | 2021-04-01 → 2022-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥2.1bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Investing cash flow | ¥4.5bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥14.7bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥6.7bn | 2022-04-01 → 2023-03-31v | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥1.5bn | 2021-04-01 → 2022-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥2.4bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Financing cash flow | −¥7.6bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | ¥14.4bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | ¥4.0bn | 2022-04-01 → 2023-03-31v | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥4.4bn | 2021-04-01 → 2022-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥591m | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| EPS (basic) | ¥106.81 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥93.99 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥113.9 | 2022-04-01 → 2023-03-31v | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥129.68 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥52.71 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥106.81 | 2024-04-01 → 2025-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥93.99 | 2023-04-01 → 2024-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥113.9 | 2022-04-01 → 2023-03-31v | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥129.68 | 2021-04-01 → 2022-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥52.71 | 2020-04-01 → 2021-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| Net assets per share | ¥1,012.38 | at 2025-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥931.79 | at 2024-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥533.1 | at 2023-03-31v | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥453.12 | at 2022-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥226.83 | at 2021-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Equity ratio | 34.8% | at 2025-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 43.5% | at 2024-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 29.4% | at 2023-03-31v | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 27.4% | at 2022-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 16.6% | at 2021-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| ROE | 11.0% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 13.3% | 2023-04-01 → 2024-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 22.9% | 2022-04-01 → 2023-03-31v | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 38.1% | 2021-04-01 → 2022-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 27.1% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| Employees | 5,145 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 3,743 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 2,994 | at 2023-03-31v | Cons. | Number of employees |
| Employees | 2,470 | at 2022-03-31d | Cons. | Number of employees |
| Employees | 1,819 | at 2021-03-31d | Cons. | Number of employees |
| Revenue | ¥7.9bn | 2024-04-01 → 2025-03-31 | Standalone | Net sales |
| Revenue | ¥7.8bn | 2023-04-01 → 2024-03-31 | Standalone | Net sales |
| Revenue | ¥14.3bn | 2022-04-01 → 2023-03-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥15.4bn | 2021-04-01 → 2022-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥4.0bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥2.2bn | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Operating income | ¥2.2bn | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Ordinary income | ¥2.0bn | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥1.9bn | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥1.8bn | 2022-04-01 → 2023-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.4bn | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥795m | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥2.1bn | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥1.9bn | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Net income | ¥1.4bn | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | ¥1.3bn | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | ¥1.3bn | 2022-04-01 → 2023-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥1.7bn | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥574m | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥56.1bn | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥45.5bn | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥28.4bn | at 2023-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥23.9bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥19.4bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥32.6bn | at 2025-03-31 | Standalone | Liabilities |
| Total liabilities | ¥23.2bn | at 2024-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥23.5bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥22.3bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥8.1bn | at 2023-03-31v | Standalone | Net assets |
| Net assets / equity | ¥7.4bn | at 2022-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥3.9bn | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥1.8bn | at 2025-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥3.4bn | at 2024-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥48.63 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥46.01 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥60.21 | 2022-04-01 → 2023-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥78.53 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥25.98 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥797.1 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥759.3 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥365.69 | at 2023-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥335.57 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥176.49 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 41.6% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 48.8% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 28.4% | at 2023-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 30.9% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 20.1% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 6.2% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 8.4% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 16.6% | 2022-04-01 → 2023-03-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 30.6% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 15.9% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 29,990,400 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 29,990,400 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 113,152 | at 2023-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 104,352 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 104,352 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 467 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 434 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 423 | at 2023-03-31v | Standalone | Number of employees |
| Employees | 374 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 304 | at 2021-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 60
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2025-03-31 | 2 pure |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-04-01 → 2025-03-31 | ¥120m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-04-01 → 2025-03-31 | ¥120m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-04-01 → 2025-03-31 | ¥55m |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2025-03-31 | −¥314m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2025-03-31 | −¥314m |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2025-03-31 | −¥834m |
| Hospicereportable segment | employees | at 2025-03-31 | 1864 pure |
| Hospicereportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥13.8bn |
| Hospicereportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥13.8bn |
| Hospicereportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥1.0bn |
| In Home Nursingreportable segment | employees | at 2025-03-31 | 1591 pure |
| In Home Nursingreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥12.3bn |
| In Home Nursingreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥12.3bn |
| In Home Nursingreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥0 |
| In Home Nursingreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥1.2bn |
| Medical Care Residencereportable segment | employees | at 2025-03-31 | 759 pure |
| Medical Care Residencereportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥3.6bn |
| Medical Care Residencereportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥3.6bn |
| Medical Care Residencereportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥299m |
| Medical Institutionreportable segment | employees | at 2025-03-31 | 800 pure |
| Medical Institutionreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥17.6bn |
| Medical Institutionreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥17.3bn |
| Medical Institutionreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥314m |
| Medical Institutionreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥3.6bn |
| —segment total | revenue | 2024-04-01 → 2025-03-31 | ¥47.2bn |
| —segment total | revenue external | 2024-04-01 → 2025-03-31 | ¥46.9bn |
| —segment total | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥314m |
| —segment total | segment profit | 2024-04-01 → 2025-03-31 | ¥6.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2025-03-31 | ¥47.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2025-03-31 | ¥47.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥314m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2025-03-31 | ¥6.2bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-04-01 → 2024-03-31 | ¥205m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-04-01 → 2024-03-31 | ¥205m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-04-01 → 2024-03-31 | ¥18m |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2024-03-31 | −¥264m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2024-03-31 | −¥264m |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2024-03-31 | −¥1.2bn |
| Hospicereportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥10.4bn |
| Hospicereportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥10.4bn |
| Hospicereportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥1m |
| Hospicereportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥405m |
| In Home Nursingreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥10.9bn |
| In Home Nursingreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥10.9bn |
| In Home Nursingreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥0 |
| In Home Nursingreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥616m |
| Medical Institutionreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥11.8bn |
| Medical Institutionreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥11.5bn |
| Medical Institutionreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥263m |
| Medical Institutionreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥3.9bn |
| —segment total | revenue | 2023-04-01 → 2024-03-31 | ¥33.1bn |
| —segment total | revenue external | 2023-04-01 → 2024-03-31 | ¥32.8bn |
| —segment total | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥264m |
| —segment total | segment profit | 2023-04-01 → 2024-03-31 | ¥4.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2024-03-31 | ¥33.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2024-03-31 | ¥33.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥264m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2024-03-31 | ¥4.9bn |
| Medical Institutionreportable segment | employees | at 2025-03-31 | 338 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,878
| Item | Context | Value | Unit |
|---|---|---|---|
| Equity attributable to owners of parent IFRS (5-year summary) | Prior3YearInstant | 9457000000 | JPY |
| Equity attributable to owners of parent IFRS (5-year summary) | Prior2YearInstant | 11704000000 | JPY |
| Equity attributable to owners of parent IFRS (5-year summary) | Prior1YearInstant | 27316000000 | JPY |
| Equity attributable to owners of parent IFRS (5-year summary) | CurrentYearInstant | 29678000000 | JPY |
| Total assets IFRS (5-year summary) | Prior4YearInstant | 28449000000 | JPY |
| Total assets IFRS (5-year summary) | Prior3YearInstant | 34526000000 | JPY |
| Total assets IFRS (5-year summary) | Prior2YearInstant | 39750000000 | JPY |
| Total assets IFRS (5-year summary) | Prior1YearInstant | 62836000000 | JPY |
| Total assets IFRS (5-year summary) | CurrentYearInstant | 85167000000 | JPY |
| Equity to asset ratio IFRS (5-year summary) | Prior4YearInstant | 226.83 | |
| Equity to asset ratio IFRS (5-year summary) | Prior3YearInstant | 453.12 | |
| Equity to asset ratio IFRS (5-year summary) | Prior2YearInstant | 533.10 | |
| Equity to asset ratio IFRS (5-year summary) | Prior1YearInstant | 931.79 | |
| Equity to asset ratio IFRS (5-year summary) | CurrentYearInstant | 1012.38 | |
| Basic earnings loss per share IFRS (5-year summary) | Prior4YearDuration | 52.71 | |
| Basic earnings loss per share IFRS (5-year summary) | Prior3YearDuration | 129.68 | |
| Basic earnings loss per share IFRS (5-year summary) | Prior2YearDuration | 113.90 | |
| Basic earnings loss per share IFRS (5-year summary) | Prior1YearDuration | 93.99 | |
| Basic earnings loss per share IFRS (5-year summary) | CurrentYearDuration | 106.81 | |
| Diluted earnings loss per share IFRS (5-year summary) | Prior4YearDuration | 52.71 | |
| Diluted earnings loss per share IFRS (5-year summary) | Prior3YearDuration | 129.68 | |
| Diluted earnings loss per share IFRS (5-year summary) | Prior2YearDuration | 113.90 | |
| Diluted earnings loss per share IFRS (5-year summary) | Prior1YearDuration | 93.99 | |
| Diluted earnings loss per share IFRS (5-year summary) | CurrentYearDuration | 106.81 | |
| Ratio of owners equity to gross assets IFRS (5-year summary) | Prior4YearInstant | 0.166 | |
| Ratio of owners equity to gross assets IFRS (5-year summary) | Prior3YearInstant | 0.274 | |
| Ratio of owners equity to gross assets IFRS (5-year summary) | Prior2YearInstant | 0.294 | |
| Ratio of owners equity to gross assets IFRS (5-year summary) | Prior1YearInstant | 0.435 | |
| Ratio of owners equity to gross assets IFRS (5-year summary) | CurrentYearInstant | 0.348 | |
| Rate of return on equity IFRS (5-year summary) | Prior4YearDuration | 0.271 | |
| Rate of return on equity IFRS (5-year summary) | Prior3YearDuration | 0.381 | |
| Rate of return on equity IFRS (5-year summary) | Prior2YearDuration | 0.229 | |
| Rate of return on equity IFRS (5-year summary) | Prior1YearDuration | 0.133 | |
| Rate of return on equity IFRS (5-year summary) | CurrentYearDuration | 0.110 | |
| Price earnings ratio IFRS (5-year summary) | Prior4YearDuration | － | |
| Price earnings ratio IFRS (5-year summary) | Prior3YearDuration | － | |
| Price earnings ratio IFRS (5-year summary) | Prior2YearDuration | － | |
| Price earnings ratio IFRS (5-year summary) | Prior1YearDuration | 28.76 | |
| Price earnings ratio IFRS (5-year summary) | CurrentYearDuration | 12.84 | |
| Cash flows from used in operating activities IFRS (5-year summary) | Prior4YearDuration | 2122000000 | JPY |
| Cash flows from used in operating activities IFRS (5-year summary) | Prior3YearDuration | 6616000000 | JPY |
| Cash flows from used in operating activities IFRS (5-year summary) | Prior2YearDuration | 2357000000 | JPY |
| Cash flows from used in operating activities IFRS (5-year summary) | Prior1YearDuration | 4156000000 | JPY |
| Cash flows from used in operating activities IFRS (5-year summary) | CurrentYearDuration | 2503000000 | JPY |
| Cash flows from used in investing activities IFRS (5-year summary) | Prior4YearDuration | -2420000000 | JPY |
| Cash flows from used in investing activities IFRS (5-year summary) | Prior3YearDuration | -1468000000 | JPY |
| Cash flows from used in investing activities IFRS (5-year summary) | Prior2YearDuration | -6682000000 | JPY |
| Cash flows from used in investing activities IFRS (5-year summary) | Prior1YearDuration | -14746000000 | JPY |
| Cash flows from used in investing activities IFRS (5-year summary) | CurrentYearDuration | 4450000000 | JPY |
| Cash flows from used in financing activities IFRS (5-year summary) | Prior4YearDuration | -591000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 21 of 21 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |